Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men

被引:28
作者
Andrews, J. [1 ]
Honeybourne, D.
Ashby, J.
Jevons, G.
Fraise, A.
Fry, P.
Warrington, S.
Hawser, S.
Wise, R.
机构
[1] City Hosp NHS Trust, Dept Med Microbiol, Birmingham, W Midlands, England
[2] Heartlands NHS Trust, Dept Resp Med, Birmingham, W Midlands, England
[3] Cent Middlesex Hosp, Hammersmith Med Res Ltd, London NW10 7NS, England
[4] Arpida, Reinach, Switzerland
关键词
diaminopyrimidine; concentration; respiratory tree;
D O I
10.1093/jac/dkm242
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A validated microbiological assay was used to measure concentrations of iclaprim (AR-100) in plasma, bronchial mucosa (BM), alveolar macrophages (AM) and epithelial lining fluid (ELF) after a single 1.6 mg/kg intravenous 60 min iv infusion of iclaprim. Methods: Male volunteers were randomly allocated to three nominal sampling time intervals 1-2 h (Group A), 3-4 h (Group B) and 5.5-7.0 h (Group C) after the start of the drug infusion. Results: Mean iclaprim concentrations in plasma, BM, AM and ELF, respectively, were for Group A 0.59 mg/L (SD 0.18), 0.51 mg/kg (SD 0.17), 24.51 mg/L (SD 21.22) and 12.61 mg/L (SD 7.33); Group B 0.24 mg/L (SD 0.05), 0.35 mg/kg (SD 0.17), 7.16 mg/L (SD 1.91) and 6.38 mg/L (SD 5.17); and Group C 0.14 mg/L (SD 0.05), no detectable level in BM, 5.28 mg/L (SD 2.30) and 2.66 mg/L (SD 2.08). Conclusions: Iclaprim concentrations in ELF and AM exceeded the MIC90 for penicillin-susceptible Streptococcus pneumoniae (MIC90 0.06 mg/L), penicillin-intermediate S. pneumoniae (MIC90 2mg/L), penicillin-resistant S. pneumoniae (MIC90 4 mg/L) for 7, 7 and 4 h, respectively, and Chlamydia pneumoniae (MIC90 0.5 mg/L) for 7 h. Mean iclaprim concentrations in ELF exceeded the MIC90 for Haemophilus influenzae (MIC90 4 mg/L) and Moraxella catarrhalis (MIC90 8 mg/L) for up to 4 and 2 h, respectively; in AM the MIC90 was exceeded for up to 7 h. Furthermore, the MIC90 for methicillin-resistant Staphylococcus aureus of 0.12 mg/L was exceeded at all sites for up to 7 h. These data suggest that iclaprim reaches lung concentrations that should be effective in the treatment of community-acquired pneumonia.
引用
收藏
页码:677 / 680
页数:4
相关论文
共 10 条
  • [1] ALLEN JG, 1978, LAB METHODS ANTIMICR, P227
  • [2] BSAC standardized disc susceptibility testing method (version 3)
    Andrews, JM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) : 713 - 728
  • [3] Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy
    Andrews, JM
    Honeybourne, D
    Brenwald, NP
    Bannerjee, D
    Iredale, M
    Cunningham, B
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (06) : 797 - 802
  • [4] BENNET JV, 1996, APPL MICROBIOL, V14, P170
  • [5] TRIMETHOPRIM IN NORMAL AND PATHOLOGICAL HUMAN LUNG-TISSUE
    HANSEN, I
    NIELSEN, ML
    HEERFORDT, L
    HENRIKSEN, B
    BERTELSEN, S
    [J]. CHEMOTHERAPY, 1973, 19 (04) : 221 - 234
  • [6] HANSEN I, 1973, ACTA PHARMACOL TOX, V32, P337
  • [7] JOHN BA, 2005, 45 INT C ANT AG CHEM
  • [8] THE DIAGNOSIS OF MILD EMPHYSEMA - CORRELATION OF COMPUTED-TOMOGRAPHY AND PATHOLOGY SCORES
    KUWANO, K
    MATSUBA, K
    IKEDA, T
    MURAKAMI, J
    ARAKI, A
    NISHITANI, H
    ISHIDA, T
    YASUMOTO, K
    SHIGEMATSU, N
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (01): : 169 - 178
  • [9] Iclaprim. Antibacterial, dihydrofolate reductase inhibitor
    Sorbera, LA
    Castaner, J
    Rabasseda, X
    [J]. DRUGS OF THE FUTURE, 2004, 29 (03) : 220 - 225
  • [10] A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses
    Wise, R
    Honeybourne, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 : 57 - 63